Gelonghui, January 30, 丨 Changyao Holdings (300391.SZ) announced its 2023 annual results forecast. Net profit loss attributable to shareholders of listed companies during the reporting period was 50 million yuan to 70 million yuan, loss of 23.2733 million yuan for the same period of the previous year; net profit loss after deducting non-recurring profit and loss of 575 million yuan to 775 million yuan, loss of 76.3948 million yuan for the same period last year; operating income of 110,000 yuan to 130,000 yuan after deduction .

In 2023, in order to accelerate the repayment of accounts receivable, the company's pharmaceutical sector appropriately controlled deliveries and reduced channel inventory based on objective market conditions and actual product sales. At the same time, due to intense competition in the industry, the company's operating income and gross margin declined significantly, with a significant year-on-year decline.

The company estimates asset impairment losses and credit impairment losses for this year to be around 800 million yuan. Among them, goodwill impairment losses are estimated to be around 450 million yuan, fixed asset impairment losses are estimated to be around 120 million yuan, and preparation for bad accounts receivable is estimated to be around 200 million yuan.